TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02954523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: oral every day
Study: NCT02971410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study: NCT02954523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: oral every day
Study: NCT01279499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol- Remifentanyl
Description: Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, Remifentanyl
Description: Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min
Study: NCT00038051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hum-195/rGel
Description: Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
Study: NCT01896570

Intervention type: PROCEDURE
Intervention: Catheter ablation of subsequent atrial tachycardia
Study: NCT03873948

Intervention type: OTHER
Intervention: Evaluation of arginine serum level
Description: correlation of serum arginine level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Evaluation of arginine serum level
Description: correlation of serum arginine level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Evaluation of arginine serum level
Description: correlation of serum arginine level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Evaluation of arginine serum level
Description: correlation of serum arginine level with periodontal and cardiovascular disease
Study: NCT01201148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Eldith DC-Stimulator (CE certified))
Description: For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
Study: NCT03371940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program ACTIVE Exercise
Description: Please see the Exercise arm description above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program ACTIVE CBT
Description: Please see the Talk Therapy arm description above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program ACTIVE
Description: Please see the Talk Therapy + Exercise arm description above.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care - No intervention
Description: Please see the Usual Care arm description above.
Study: NCT03119324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure® diode laser
Description: B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: B-Cure® diode laser sham device
Description: B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimesulide Ratiopharm® and Flexiban®
Description: Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
Study: NCT03498833

Intervention type: OTHER
Group type: OTHER
Intervention: Test-retest reliability testing
Description: Set of patient reported outcome measures
Study: NCT02813837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CART
Description: Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
Study: NCT00729404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
Study: NCT04048824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory Learning-Based Exposure
Description: 9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habituation-Based Exposure
Description: 9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
Study: NCT00644397

Intervention type: DEVICE
Intervention: 95-degree Angled Blade Plate

Intervention type: DEVICE
Intervention: 4.5mm Condylar Locking Plate
Study: NCT03609567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy using essential oils

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aromatherapy using odorless placebo oil
Study: NCT00269035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB773812
Description: SB-773812 tablets will be available with dose strength of 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB773812
Description: SB-773812 tablets will be available with dose strength of 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone tablets will be available with dose strength of 3 and 6 mg
Study: NCT01636180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
Study: NCT03388021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: completion angiography followed by endovascular treatment of residual or underlying lesions
Description: completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: completion angiography followed by endovascular treatment of residual or underlying lesions
Description: completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
Study: NCT00485914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site work evaluation
Description: Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational material
Description: Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
Study: NCT02884206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Valsartan
Description: Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
Study: NCT02363010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Behavior Therapy for Weight Loss
Description: Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Behavior Therapy for Weight Loss
Description: Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gold Standard Behavior Therapy for Weight Loss
Description: Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy for Weight Loss with Physical Activity Emphasis
Description: Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavior Therapy for Weight Loss with PA emphasis
Description: Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
Study: NCT04184310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified perineal linear stapler resection for external rectal prolapse
Description: After anesthesia and patient position, the prolapse was pulled out Two vertical incision were made in both the inner and outer walls of the prolapse (at 3and 9 o'clock)1-2 cm in size approximately 2 cm above the dentate line. We used a reloadable linear cutter stapler (GIA 100mm Covidien, Mansfield, Mass., USA) passing through the tunnel to cut the anterior aspect of the prolapse . Then, after reload the stapler by the new cartridge, we used it to do the same for posterior wall and the prolapsed rectum was completely transected . We ensure that the stapler did not fire at the dentate line to avoid post-operative pain. Multiple 3-0 PDS intermittent full thickness sutures were done for hemostasis. The prolapsed rectum falls back into place spontaneously.
Study: NCT02160197

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aircast XP Walker boot
Description: Ankle boot allowing weight bearing as tolerated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster Immobilisation
Description: Plaster immobilisation with no weight bearing allowed.
Study: NCT02903433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intake avocados
Description: Families will receive 14 avocados on a weekly basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intake avocados
Description: Families will receive 3 avocados on a weekly basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet tips
Description: Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet tips
Description: Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avocado consumption advice
Description: Recipe book with healthy recipe suggestions that include avocado.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Avocado consumption advice
Description: Recipe book with healthy recipe suggestions that include avocado.
Study: NCT03216733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBO
Description: PCI with COMBO stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORSIRO
Description: PCI with ORSIRO stent
Study: NCT03980379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 304 injection
Description: Monoclonal antibodies, 100mg/10ml per injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab injection
Description: 100mg/10ml per injection ，manufactured by Roche
Study: NCT04546906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
Study: NCT02004847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSO-CT02
Description: The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSO-CT02
Description: The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
Study: NCT00799006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given placebo or PF-04620110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
Study: NCT04413747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: morning Yoga-based breathing support
Description: Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre_lunch Yoga-based breathing support
Description: Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre_dinner Yoga-based breathing support
Description: Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
Study: NCT01081184

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
Study: NCT02278679

Intervention type: PROCEDURE
Intervention: Digital Rectal Exam
Description: The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
Study: NCT02383147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomographic Neurofeedback
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Tomographic Neurofeedback
Description: EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
Study: NCT04653870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cyriax manipulation lumber
Description: In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams \& Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week.
Study: NCT02582242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
Study: NCT00862823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir, emtricitabine and efavirenz fixed dose tablet
Description: Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir, emtricitabine and efavirenz tablet added to solution
Description: Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
Study: NCT02653144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery